Cotrimoxazole Preventive Therapy in Malawi
Author Information
Author(s): Harries Anthony D, Zachariah Rony, Chimzizi Rhehab, Salaniponi Felix, Gausi Francis, Kanyerere Henry, Schouten Erik J, Jahn Andreas, Makombe Simon D, Chimbwandira Frank M, Mpunga James
Primary Institution: International Union against Tuberculosis and Lung Disease, Paris, France
Hypothesis
Does cotrimoxazole preventive therapy reduce death rates in tuberculosis patients co-infected with HIV and those starting antiretroviral treatment?
Conclusion
The implementation of cotrimoxazole preventive therapy was associated with reduced death rates in both tuberculosis patients and HIV-infected patients starting antiretroviral treatment.
Supporting Evidence
- Cotrimoxazole significantly reduced case fatality rates in HIV-infected TB patients.
- The policy changes were based on rapid dissemination of research findings.
- Monitoring tools and training packages were developed to support the implementation of the new policy.
- National programme performance improved with a significant decrease in early death rates.
Takeaway
Giving a medicine called cotrimoxazole to people with tuberculosis and HIV helps them live longer and healthier lives.
Methodology
District and facility-based operational research was conducted to assess the effectiveness of cotrimoxazole preventive therapy in reducing death rates.
Potential Biases
Potential bias from self-reported adherence to treatment and the reliance on historical controls.
Limitations
The study did not assess the long-term effects of cotrimoxazole on drug resistance.
Participant Demographics
Participants included tuberculosis patients, primarily co-infected with HIV, from various districts in Malawi.
Statistical Information
P-Value
0.0013
Statistical Significance
p<0.0013
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website